----

----

| x      | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934     |
|--------|------------------------------------------------------------------------------------------|
|   |                                                                                     |
|   | For the fiscal year ended December 31, 2009                                              |
| OR     |
|   |                                                                                     |
| o      | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|   |                                                                                     |
|   | For the transition period from____________ to __________                                 |
|   | Commission file number 0-8527                                                            |

|                            FLORIDA                           |                            59-1757642                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (State or other jurisdiction of                                                                                                                                                                                                                                                                                                  | (I.R.S. Employer                                                                                                                                                                                                                                                                                                                    |
| incorporation or organization)                                                                                                                                                                                                                                                                                                   | Identification No.)                                                                                                                                                                                                                                                                                                                 |

| 1302 CONCOURSE DRIVE, SUITE 204, LINTHICUM, MARYLAND                           |                            21090                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (Address of principal executive offices)                                                                                                                                                                         | (Zip Code)                                                                                                                                                                                                                                                                                                                     |

| Title of Each Class          | Name of Each Exchange on Which Registered |
|------------------------------|-------------------------------------------|
| common stock, $.01 par value | The NASDAQ Stock Market, LLC              |
|                         | (NASDAQ Global Market)                    |

| Yes o | No x |
|-------|------|

| Yes o | No x |
|-------|------|

| Large accelerated filer o | Accelerated filer x | Non-accelerated filer o | Smaller reporting company o |
|---------------------------|---------------------|-------------------------|-----------------------------|

----

----

----

----

| Name                | Age    | Current Position             | Held Since |
|---------------------|--------|------------------------------|------------|
|                |   |                         |       |
| Thomas K. Langbein  | 64     | Chairman of the Board and    | 1980       |
|                |   | Chief of Strategic Alliances |       |
|                |   | and Investor Relations       | 2009       |
|                |   |                         |       |
| Stephen W. Everett  | 53     | President and director       | 2000       |
|                |   | CEO                          | 2003       |
|                |   |                         |       |
| Peter D. Fischbein* | 70     | Director                     | 2004       |
|                |   |                         |       |
| Robert W. Trause*   | 67     | Director                     | 1998       |
|                |   |                         |       |
| Kenneth J. Bock **  | 57     | Director                     | 2009       |

| *      | Member of the Audit, Compensation and Nominating Committees                                                                                                                                                                                             |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                    |
| **     | Chairman of the Audit Committee and a member of the Compensation and Nominating Committees; Mr. Bock is the Audit Committee financial expert.  See “Corporate Governance – Board Committees – Audit Committee” below. |

----

|   | ● | Leadership experience as past and current Chairman of the Board, both of the company and its former parent, Medicore, Inc., which merged with the company in 2005; each a public company |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | ● | Master’s Degree in Finance                                                                                                                                                         |
|   | ● | Finance experience                                                                                                                                                                       |
|   | ● | Former President and owner of broker-dealer registered with the SEC; many years of security industry experience                                                                          |
|   | ● | Largest shareholder of the company                                                                                                                                                       |

|   | ● | Leadership experience as current President and Chief Executive Officer of the company |
|--------|---------|---------------------------------------------------------------------------------------|
|   | ● | Industry experience with more than 30 years involvement in the healthcare industry    |
|   | ● | Executive management experience with major dialysis services provider                 |
|   | ● | Experience with deal structuring, physician recruitment and practice management       |

|   | ● | Experienced counsel with litigation and class action knowledge                                   |
|--------|---------|--------------------------------------------------------------------------------------------------|
|   | ● | Outside board experience with other public companies, including Medicore, Inc. and Viragen, Inc. |
|   | ● | Experience in business structuring                                                               |

----

|   | ● | Insurance industry expertise                                         |
|--------|---------|----------------------------------------------------------------------|
|   | ● | Board leadership qualities with years of experience with the company |
|   | ● | Marketing experience                                                 |

|   | ● | Experience in investment banking with emphasis in heathcare                                                  |
|--------|---------|--------------------------------------------------------------------------------------------------------------|
|   | ● | Finance experience with responsibilities in capital management and investment banking                        |
|   | ● | New business development and structured finance solutions experience                                         |
|   | ● | Former CEO and member of board of directors of global capital markets and alternative risk portfolio company |

| Name                     |   | Fees Earned orPaid in Cash($) |    |   | Stock Awards($) |   |   | All OtherCompensation($) |   |   | Total($) |   |
|--------------------------|--------|-------------------------------|---------|--------|-----------------|--------|--------|--------------------------|--------|--------|----------|--------|
| (a)                      |   | (b)                           |    |   | (c)             |   |   | (g)                      |   |   | (h)      |   |
| Thomas K. Langbein       |   | $                             | 147,000 | (1)    |            | $      | 31,320 | (2)                      |   | $      | 13,068   | (3)    |   | $ | 191,388 |   |
| Peter D. Fischbein       |   | $                             | 6,000   |   |            | $      | 15,660 | (4)(5)                   |   | $      | ---      |   |   | $ | 21,660 |   |
| Robert W. Trause         |   | $                             | 6,000   |   |            | $      | 15,660 | (4)(5)                   |   | $      | ---      |   |   | $ | 21,660 |   |
| Kenneth J. Bock(6)       |   | $                             | 5,000   |   |            | $      | 10,120 | (5)                      |   | $      | ---      |   |   | $ | 15,120 |   |
| Alexander Bienenstock(6) |   | $                             | 1,000   |   |            | $      | 5,540  | (4)                      |   | $      | ---      |   |   | $ | 6,540 |   |

----

| (1)    | Includes: (i) $144,000 portion of annual stipend of $200,000 paid until Mr. Langbein became an executive officer (Chief of Strategic Alliances and Investor Relations) in September, 2009, at which time he began receiving compensation as an employee rather than as a nonemployee director; and (ii) $3,000 nonemployee director fees. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                      |
| (2)    | Includes: (i) $11,080 grant date value of a February 27, 2009 stock award of 2,000 restricted shares that vested immediately; and (ii) $20,240 grant date value of a June 11, 2009 restricted stock unit award of 4,000 restricted shares that vest one year from the date of grant.                                                      |
|   |                                                                                                                                                                                                                                                                                                                                      |
| (3)    | Includes: (i) $11,490 health and dental insurance premiums; and (ii) $1,578 auto-related expenses.                                                                                                                                                                                                                                        |
|   |                                                                                                                                                                                                                                                                                                                                      |
| (4)    | Includes $5,540 grant date value of a February 27, 2009 stock award of 1,000 restricted shares that vested immediately.                                                                                                                                                                                                                   |
|   |                                                                                                                                                                                                                                                                                                                                      |
| (5)    | Includes $10,120 grant date value of a June 11, 2009 restricted stock unit award of 2,000 restricted shares that vest one year from the date of grant.                                                                                                                                                                                    |
|   |                                                                                                                                                                                                                                                                                                                                      |
| (6)    | Alexander Bienenstock retired as director (Chairman of the Audit Committee) on June 11, 2009, at which time Kenneth J. Bock was elected as a director and appointed as the Chairman of the Audit Committee.                                                                                                                               |

| Name                | Age    | Position                          | Held Since |
|---------------------|--------|-----------------------------------|------------|
|                |   |                              |       |
| Thomas K. Langbein* | 64     | Chairman of the Board and         | 1980       |
|                |   | Chief of Strategic Alliance       |       |
|                |   | and Investor Relations            | 2009       |
|                |   |                              |       |
| Stephen W. Everett* | 53     | President and                     | 2000       |
|                |   | CEO                               | 2003       |
|                |   |                              |       |
| Andrew J. Jeanneret | 45     | Vice President, Finance and       | 2007       |
|                |   | Chief Financial Officer           | 2008       |
|                |   |                              |       |
| Daniel R. Ouzts     | 63     | Vice President, Finance           | 2005       |
|                |   | Chief Accounting Officer          | 2009       |
|                |   | and Treasurer                     | 1996       |
|                |   |                              |       |
| Thomas P. Carey     | 56     | Vice President, Operations        | 2007       |
|                |   | Chief Operating Officer           | 2009       |
|                |   |                              |       |
| Joanne Zimmerman    | 55     | Vice President, Clinical Services | 2000       |
|                |   | and Compliance Officer            | 2007       |

| * | For information concerning Messrs. Langbein and Everett, see “The Company Board of Directors” above. |
|---|------------------------------------------------------------------------------------------------------------------|

----

----

|   | ● | is, or at any time during the past three years was, employed by the company;                                                                                                                                                                                                                                                                                                                                                                                                                     |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | ● | accepted compensation from the company in excess of $120,000 during any period of 12 consecutive months within the three years preceding the determination of independence (with certain exceptions);                                                                                                                                                                                                                                                                                            |
|   | ● | is a family member of an individual who during the past three years was employed by the company as an executive officer;                                                                                                                                                                                                                                                                                                                                                                         |
|   | ● | is a partner, controlling shareholder, or an executive officer of any organization to which the company made, or from which the company received, payments for property or services in the current or any of the past three years that exceed 5% of the recipient’s consolidated gross revenues for that year, or $200,000, whichever is greater, other than investments in the company’s securities, or payments under non-discretionary charitable contribution matching programs; |
|   | ● | is employed as an executive officer of another entity where at any time during the past three years any executive officer of the company served on the Compensation Committee of the other entity; or                                                                                                                                                                                                                                                                                            |
|   | ● | is a current partner of the company’s outside audit firm, or was an employee or partner of the company’s outside audit firm who worked on the company’s audit at any time during any of the past three years.                                                                                                                                                                                                                                                                  |

----

| Non-Employee Director | Audit  | Compensation | Nominating |
|-----------------------|--------|--------------|------------|
|                  |   |         |       |
| Kenneth J Bock        | Chair  | Member       | Member     |
| Robert W. Trause      | Member | Member       | Chair      |
| Peter D. Fischbein    | Member | Chair        | Member     |

|   | ● | annually review and approve the compensation and benefit arrangements for the CEO and senior management; the Chairman and the CEO may participate with the Compensation Committee in the review and approval of senior management compensation; |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | ● | review and recommend to the board of directors for its adoption or amendment, the compensation and benefit plans and programs for other officers and key employees, including stock option or incentive compensation plans;                     |
|   | ● | approve the terms and conditions of awards under such plans within the limits of each plan;                                                                                                                                                     |
|   | ● | review and recommend to the board of directors the form and amount of director compensation;                                                                                                                                                    |
|   | ● | approve our overall compensation strategy;                                                                                                                                                                                                      |
|   | ● | develop and approve the Compensation Committee Report; and                                                                                                                                                                                      |
|   | ● | perform other duties assigned by the board of directors that are consistent with the Compensation Committee Charter, our by-laws, and governing law.                                                                                            |

----

|   | ● | assist the board in identifying and evaluating individuals qualified for board membership; |
|--------|---------|--------------------------------------------------------------------------------------------|
|   | ● | recommend to the board nominees for directors for each annual meeting of shareholders; and |
|   | ● | recommend directors for each committee.                                                    |

----

|   | ● | name, age, business address, and, if known, residence address                                                                                                      |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | ● | principal occupation or employment for the preceding five years                                                                                                    |
|   | ● | beneficial ownership of the company’s securities, giving the number of each class of security                                                                |
|   | ● | any arrangement, affiliation, association, agreement or other relationship with any security holder, officer, director or other person affiliated with the company |
|   | ● | consent to serve as a director, if elected                                                                                                                         |
|   | ● | the name and address of the shareholder proposing the nominee and other shareholders believed to be supporting such nominee                                        |
|   | ● | the number of securities of each class owned by such nominating shareholder(s)                                                                                     |

|   | ● | discussions with the recommender;    |
|--------|---------|--------------------------------------|
|   | ● | due diligence checks of the nominee; |
|   | ● | interviews with the nominee; and     |
|   | ● | needs of the board.                  |

----

|   | ● | the scope of the Audit Committee’s responsibilities;      |
|--------|---------|-----------------------------------------------------------------|
|   | ● | how the Audit Committee carries out those responsibilities; and |
|   | ● | structure, processes and membership requirements.               |

----

|   | ● | email to Thomas K. Langbein, the Chairman of the Board of Directors, at TLangbein@dialysiscorporation.com;                                                                                              |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | ● | mail to any member of the board, c/o Dialysis Corporation of America, either at 1302 Concourse Drive, Suite 204, Linthicum, Maryland 21090, or 777 Terrace Avenue, Hasbrouck Heights, New Jersey 07604; |
|   | ● | fax to Thomas K. Langbein, the Chairman of the Board of Directors, (201) 288-8208;                                                                                                                      |
|   | ● | email to counsel to the company, Jaffe Law, LLC, attention Joshua M. Jaffe, Esq., who is also the Secretary to the company, at jmj@lawjaffe.com; and                                                    |
|   | ● | by telephone, Thomas K. Langbein at (201) 288-8222, or Joshua M. Jaffe at (201) 288-8282.                                                                                                               |

----

|   | ● | performance, individually and as a team-member;                                  |
|--------|---------|----------------------------------------------------------------------------------|
|   | ● | roles and responsibilities;                                                      |
|   | ● | overall contribution to DCA, and encouragement and recognition of career growth; |
|   | ● | competitiveness with other business opportunities;                               |
|   | ● | experience, skills and talents;                                                  |
|   | ● | providing incentives that encourage retention of our executive officers;         |
|   | ● | improvement of the company’s performance; and                              |
|   | ● | comparisons to benchmark companies.                                              |

|   | ● | recommending to the Compensation Committee base salary levels, annual bonus awards, and long-term participation levels for the Named Executive Officers and senior management; |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | ● | outlining performance and progress in meeting company objectives; and                                                                                                          |
|   | ● | conferring, on occasion, with the Chairman of the Board with respect to salary levels and bonuses for employees, management and executives.                                    |

----

|   | ● | annual base salary;                                                         |
|--------|---------|-----------------------------------------------------------------------------|
|   | ● | potential annual cash bonus, based on corporate and individual performance; |
|   | ● | longer-term equity awards; and                                              |
|   | ● | certain other benefits (perquisites).                                       |

----

----

----

----

|   | ● | performance of the company;                                                    |
|--------|---------|--------------------------------------------------------------------------------|
|   | ● | increase, if any, in total return to stockholders;                             |
|   | ● | progress toward implementation of the company’s strategic business plan; |
|   | ● | expertise;                                                                     |
|   | ● | market knowledge; and                                                          |
|   | ● | decision making and other leadership capabilities.                             |

|   | ● | participation in benefit plans and programs available to other senior executives;                                                                                                                                                                                                                                         |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | ● | reimbursement for business expenses;                                                                                                                                                                                                                                                                                      |
|   | ● | indemnification for services to the company;                                                                                                                                                                                                                                                                              |
|   | ● | non-competition with the company during the term of the employment agreement and for a period of one year after termination, which includes not diverting business from or soliciting any officers, directors, employees, suppliers, physicians or others, away from or terminating their relationships with the company; |
|   | ● | restrictions regarding confidential and proprietary information; and                                                                                                                                                                                                                                                      |
|   | ● | severance payments (see below under “Termination Payments”).                                                                                                                                                                                                                                                  |

----

----

|   | ● | mix of pay – the Committee determines each element of pay individually, targeted on company and individual performance; such reflects our financial results and share price, which we believe motivates executives to consider the impact of their decisions on shareholder value; |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | ● | compensation levels are weighted toward long-term, equity-based incentive awards with vesting schedules that materialize over a number of years;                                                                                                                                         |
|   | ● | incentive awards are selectively granted, are not automatic or annual; and                                                                                                                                                                                                               |
|   | ● | although we have no specific ownership guidelines, executives are encouraged to have an ownership interest in the company, and restricted stock awards and restricted stock units are issued from time to time as performance and bonus appropriate.                                     |

----

|   | ● | automobile allowance;                                                                                                           |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------|
|   | ● | premiums for medical and dental insurance in excess of normal employee paid portion of premiums; and                            |
|   | ● | premiums for voluntary life insurance and long-term disability insurance for our President and CEO and Chief Financial Officer. |

----

|   | ● | the maximum number of shares of company common stock subject to stock options or stock appreciation rights that may be granted to a participant in a 12 month period is 200,000, provided that in a grantee’s year of hire the applicable limit is 400,000 shares of common stock.         |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | ● | the maximum number of shares of company common stock that may be granted to a participant, other than pursuant to an option or stock appreciation right, is 200,000 per 12 month period, provided that in a grantee’s year of hire the applicable limit is 400,000 shares of common stock. |
|   | ● | the maximum amount that may be paid as an annual incentive award or other cash award in any 12 month period to any one person is $400,000.                                                                                                                                                       |
|   | ● | the maximum amount that may be paid as a performance award or other cash award in respect to a performance period to any one participant is $300,000 multiplied by the number of years in the performance period.                                                                                |

----

----

|   | ● | net earnings or net income;                                                                                              |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------|
|   | ● | operating earnings or income;                                                                                            |
|   | ● | pretax earnings;                                                                                                         |
|   | ● | earnings per share;                                                                                                      |
|   | ● | share price, including growth and capitalization measures and total stockholder return;                                  |
|   | ● | earnings before interest and taxes;                                                                                      |
|   | ● | earnings before interest, taxes, depreciation and/or amortization;                                                       |
|   | ● | sales or revenue growth;                                                                                                 |
|   | ● | gross or operating margins;                                                                                              |
|   | ● | return measures, including return on assets, capital, investment, equity, sales or revenue;                              |
|   | ● | cash flow, including operating cash flow, free cash flow, cash flow return on equity and cash flow return on investment; |
|   | ● | productivity ratios;                                                                                                     |
|   | ● | expense targets;                                                                                                         |
|   | ● | market share;                                                                                                            |
|   | ● | financial ratios as provided in credit agreements or indentures of the company and its subsidiaries;                     |
|   | ● | debt rating targets;                                                                                                     |
|   | ● | working capital targets;                                                                                                 |
|   | ● | completion of acquisitions or divestitures of businesses, assets, companies or facilities;                               |
|   | ● | employee retention and recruiting metrics, including turnover;                                                           |
|   | ● | growth in patient census; and                                                                                            |
|   | ● | clinical outcomes.                                                                                                       |

----

----

|   | Peter D. Fischbein, Chairman |   |
|--------|------------------------------|--------|
|   | Robert W. Trause             |   |
|   | Kenneth Bock                 |   |

----

|   | ● | upon the death or disability, termination by the company without cause, or by the executive officer for good reason, the company shall pay (if death, to any designated beneficiary in equal increments over 12 months from termination, except under the Everett and Langbein Employment Agreements a lump sum) including:                                                                                                                                                                                                               |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |    | (i)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |   | any portion of base salary and bonus, if any, due and payable to the date of termination; |
|   |    | (ii)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |   | one year’s base salary as of the date of termination; |
|   |    | (iii)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |   | any reimbursable expenses incurred to the date of termination; |
|   |    | (iv)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |   | non-forfeitable benefits; and |
|   |    | (v)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |   | any vested restricted stock grants not yet issued. |
|   | ● | With respect to disability (defined as the officer’s inability to perform his or her duties and responsibilities for a period of no less than 13 consecutive weeks for the Everett and Langbein Employment Agreements, and eight consecutive weeks for the other executive officers, as a result of physical or mental illness or injury), the company’s obligation for payments as detailed above is reduced by any disability payments and benefits received and to be received by the officer pursuant to such disability. |
|   | ● | With respect to termination for cause, the company’s only obligation shall be a payment for any unpaid base salary and bonus, if any, to the date of termination;                                                                                                                                                                                                                                                                                                                                                                   |
|   | ● | With respect to change in control:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |    | ▪                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |  payment as described in subparagraphs (i) to (v) above, except with respect to subparagraph (ii), the base salary (at the time of termination) payment shall be two years under the Everett and Langbein Employment Agreements, and one year for the other executive officers; |
|   |    | ▪                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |  payment only on condition that either the executive officer chooses not to continue in any capacity or affiliation with the acquiring or surviving company (including other parties affiliated or associated with the acquiring or surviving company), or the acquiring or surviving party does not wish to continue any affiliation or association with the executive officer; and |
|   |    | ▪                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |  accelerated vesting of any equity awards then owned and not vested. |

----

|                         |   | Terminationby Executivewith Good Reasonor by Companyw/o Cause |    |   |   Change inControl |   |    |   Death of theExecutive |   |   |   Disability of theExecutive |   |
|------------------------------|--------|---------------------------------------------------------------|---------|--------|------------------------------|--------|---------|-----------------------------------|--------|--------|----------------------------------------|--------|
|                         |   |                                                          |    |   |                         |   |    |                              |   |   |                                   |   |
| Thomas K. Langbein           |   |                                                          |    |   |                         |   |    |                              |   |   |                                   |   |
| Base Salary                  |   | $                                                             | 356,318 | (1)    |                         | $      | 712,636 | (2)                               |   | $      | 356,318                                | (1)    |   | $ | 296,318 | (3) |
| Other Consideration          |   | $                                                             | ---     |   |                         | $      | ---     |                              |   | $      | ---                                    |   |   | $ | --- |   |
| Restricted Stock or Options  |   | $                                                             | ---     |   |                         | $      | 45,000  | (5)                               |   | $      | ---                                    |   |   | $ | --- |   |
| Benefits and Perquisites     |   | $                                                             | 16,818  | (4)    |                         | $      | 16,818  | (4)                               |   | $      | ---                                    |   |   | $ | 16,818 | (4) |
|                         |   |                                                          |    |   |                         |   |    |                              |   |   |                                   |   |   |   |   |   |
| Stephen W. Everett           |   |                                                          |    |   |                         |   |    |                              |   |   |                                   |   |   |   |   |   |
| Base Salary                  |   | $                                                             | 365,282 | (1)    |                         | $      | 730,564 | (2)                               |   | $      | 365,282                                | (1)    |   | $ | 305,282 | (3) |
| Other Consideration          |   | $                                                             | ---     |   |                         | $      | ---     |                              |   | $      | ---                                    |   |   | $ | --- |   |
| Restricted Stock or Options  |   | $                                                             | ---     |   |                         | $      | 337,500 | (5)                               |   | $      | ---                                    |   |   | $ | --- |   |
| Benefits and perquisites (4) |   | $                                                             | 20,559  | (4)    |                         | $      | 20,559  | (4)                               |   | $      | ---                                    |   |   | $ | 20,559 | (4) |
|                         |   |                                                          |    |   |                         |   |    |                              |   |   |                                   |   |   |   |   |   |
| Andrew J. Jeanneret          |   |                                                          |    |   |                         |   |    |                              |   |   |                                   |   |   |   |   |   |
| Base Salary                  |   | $                                                             | 240,850 | (1)    |                         | $      | 240,850 | (1)                               |   | $      | 240,850                                | (1)    |   | $ | 180,850 | (3) |
| Other Consideration          |   | $                                                             | ---     |   |                         | $      | 200,000 | (6)                               |   | $      | ---                                    |   |   | $ | --- |   |
| Restricted Stock or Options  |   | $                                                             | ---     |   |                         | $      | 168,750 | (5)                               |   | $      | ---                                    |   |   | $ | --- |   |
| Benefits and perquisites (4) |   | $                                                             | 20,559  | (4)    |                         | $      | 20,559  | (4)                               |   | $      | ---                                    |   |   | $ | 20,559 | (4) |
|                         |   |                                                          |    |   |                         |   |    |                              |   |   |                                   |   |   |   |   |   |
| Thomas P. Carey              |   |                                                          |    |   |                         |   |    |                              |   |   |                                   |   |   |   |   |   |
| Base Salary                  |   | $                                                             | 219,471 | (1)    |                         | $      | 219,471 | (1)                               |   | $      | 219,471                                | (1)    |   | $ | 189,471 | (3) |
| Other Consideration          |   | $                                                             | ---     |   |                         | $      | 200,000 | (6)                               |   | $      | ---                                    |   |   | $ | --- |   |
| Restricted Stock or Options  |   | $                                                             | ---     |   |                         | $      | 247,500 | (5)                               |   | $      | ---                                    |   |   | $ | --- |   |
| Benefits and perquisites(4)  |   | $                                                             | 8,409   | (4)    |                         | $      | 8,409   | (4)                               |   | $      | ---                                    |   |   | $ | 8,409 | (4) |
|                         |   |                                                          |    |   |                         |   |    |                              |   |   |                                   |   |   |   |   |   |
| Joanne Zimmerman             |   |                                                          |    |   |                         |   |    |                              |   |   |                                   |   |   |   |   |   |
| Base Salary                  |   | $                                                             | 190,594 | (1)    |                         | $      | 190,594 | (1)                               |   | $      | 190,594                                | (1)    |   | $ | 160,594 | (3) |
| Other Consideration          |   | $                                                             | ---     |   |                         | $      | ---     |                              |   | $      | ---                                    |   |   | $ | --- |   |
| Restricted Stock or Options  |   | $                                                             | ---     |   |                         | $      | 168,750 | (5)                               |   | $      | ---                                    |   |   | $ | --- |   |
| Benefits and perquisites(4)  |   | $                                                             | 7,760   | (4)    |                         | $      | 7,760   | (4)                               |   | $      | ---                                    |   |   | $ | 7,760 | (4) |
|                         |   |                                                          |    |   |                         |   |    |                              |   |   |                                   |   |   |   |   |   |
| Daniel R. Ouzts              |   |                                                          |    |   |                         |   |    |                              |   |   |                                   |   |   |   |   |   |
| Base Salary                  |   | $                                                             | 190,594 | (1)    |                         | $      | 177,000 | (1)                               |   | $      | 177,000                                | (1)    |   | $ | 147,000 | (3) |
| Other Consideration          |   | $                                                             | ---     |   |                         | $      | ---     |                              |   | $      | ---                                    |   |   | $ | --- |   |
| Restricted Stock or Options  |   | $                                                             | ---     |   |                         | $      | 168,750 | (5)                               |   | $      | ---                                    |   |   | $ | --- |   |
| Benefits and perquisites(4)  |   | $                                                             | 20,559  | (4)    |                         | $      | 20,559  | (4)                               |   | $      | ---                                    |   |   | $ | 20,559 | (4) |

| (1) | One year’s base salary.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Two years’ base salary.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| (3) | The company’s disability payment obligation is one year’s base salary less any payments received by the individual from insurance coverage pursuant to such disability.  The above table assumes disability benefit payments of $5,000 monthly for one year under insurance policies covering Thomas K. Langbein, Stephen W. Everett and Andrew J. Jeanneret and disability payments of $5,000 monthly for six months under short term disability policies for the other Named Executive Officers.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| (4) | Premiums payable on insurance plans covering the Named Executive Officers of the company.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| (5) | Grants of restricted stock units and restricted shares under the 2009 Incentive Plan that will vest upon a Change in Control (see “Summary of the 2009 Omnibus Incentive Plan – Termination – Change in Control” above) and will receive and have been valued using the consideration of $11.25 set forth in the Merger Agreement.  The grant of restricted stock units representing 4,000 shares of common stock to Mr. Langbein was made on June 11, 2009 and are otherwise due to vest on June 10, 2010.  The grants of restricted shares were as follows: Stephen W. Everett 30,000; Thomas P. Carey 22,000; Andrew J. Jeanneret 15,000; Joanne Zimmerman 15,000; Daniel R. Ouzts 15,000.  Does not include valuation of 50,000 outstanding company stock options for Andrew Jeanneret and 50,000 outstanding company stock options for Thomas P. Carey (all of which would otherwise vest upon a Change in Control) because the $12.18 per share exercise price of such options exceed the $11.25 per share consideration under the Merger Agreement. |
| (6) | Cash consideration consisting of (i) a cash bonus for Andrew J. Jeanneret of $200,000, and (ii) a cash bonus of $30,000 and non-competition covenant payment of $170,000 each for Thomas P. Carey.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

----

| Name               |   | Benefit Type                           |   |   | Payment upon Termination inConnection with a Change inControl and/or Pursuant tothe Merger Agreement |      |
|--------------------|--------|----------------------------------------|--------|--------|------------------------------------------------------------------------------------------------------|-----------|
| Thomas K. Langbein |   | Severance (1)                          |   |   | $                                                                                                    | 729,454   |   |
|               |   | Bonus (2)                              |   |   |                                                                                                 | 0         |   |
|               |   | Value of Equity Award Acceleration (3) |   |   | $                                                                                                    | 45,000    |   |
|               |   | Total Value:                           |   |   | $                                                                                                    | 774,454   |   |
|               |   |                                   |   |   |                                                                                                 |      |   |
| Stephen W. Everett |   | Severance (1)                          |   |   | $                                                                                                    | 751,123   |   |
|               |   | Bonus (2)                              |   |   |                                                                                                 | 0         |   |
|               |   | Value of Equity Award Acceleration (3) |   |   | $                                                                                                    | 337,500   |   |
|               |   | Total Value:                           |   |   | $                                                                                                    | 1,088,623 |   |
|               |   |                                   |   |   |                                                                                                 |      |   |
| Thomas P. Carey    |   | Severance (1)                          |   |   | $                                                                                                    | 227,880   |   |
|               |   | Bonus (2)                              |   |   | $                                                                                                    | 30,000    |   |
|               |   | Value of Equity Award Acceleration (3) |   |   | $                                                                                                    | 247,500   |   |
|               |   | Non-Compete Payment (4)                |   |   | $                                                                                                    | 170,000   |   |
|               |   | Total Value:                           |   |   | $                                                                                                    | 675,380   |   |
|               |   |                                   |   |   |                                                                                                 |      |   |
| Andrew Jeanneret   |   | Severance (1)                          |   |   | $                                                                                                    | 261,409   |   |
|               |   | Bonus (2)                              |   |   | $                                                                                                    | 200,000   |   |
|               |   | Value of Equity Award Acceleration (3) |   |   | $                                                                                                    | 168,750   |   |
|               |   | Total Value:                           |   |   | $                                                                                                    | 630,159   |   |
|               |   |                                   |   |   |                                                                                                 |      |   |
| Joanne Zimmerman   |   | Severance (1)                          |   |   | $                                                                                                    | 198,354   |   |
|               |   | Bonus (2)                              |   |   |                                                                                                 | 0         |   |
|               |   | Value of Equity Award Acceleration (3) |   |   | $                                                                                                    | 168,750   |   |
|               |   | Total Value:                           |   |   | $                                                                                                    | 367,104   |   |
|               |   |                                   |   |   |                                                                                                 |      |   |
| Daniel R. Ouzts    |   | Severance (1)                          |   |   | $                                                                                                    | 197,559   |   |
|               |   | Bonus (2)                              |   |   |                                                                                                 | 0         |   |
|               |   | Value of Equity Award Acceleration (3) |   |   | $                                                                                                    | 168,750   |   |
|               |   | Total Value:                           |   |   | $                                                                                                    | 366,309   |   |

| (1) | Represents cash payments to which the applicable Named Executive Officer is entitled pursuant to his/her employment agreement representing amounts attributable to base salary and benefits, as outlined and described above.                                                                                                                                                                                                                                                                                                                                                                                  |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Represents cash payments to which the applicable Named Executive Officer is entitled upon a change in control.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| (3) | Represents the value of equity awards that would accelerate upon the expiration of the Offer. The value of the acceleration of such awards was calculated based on the Offer Price multiplied by the number of unvested equity awards that would be accelerated under the terms of the Named Executive Officer’s respective restricted stock unit award or restricted stock award. Assumes that no additional equity awards were granted between the expiration of the Offer and the termination of employment so that all equity awards would have fully vested prior to any termination of employment. |
| (4) | Assuming the Merger is consummated, Mr. Carey will receive a payment of $170,000 for agreeing to amend his employment agreement, as described above under “Analysis of Executive Compensation.”                                                                                                                                                                                                                                                                                                                                                                                                    |

----

| Name andPrincipal Position   |   | Year   |   | Salary($) |    |   | Bonus($) |   |   | StockAwards($) |   |   | OptionAwards($) |   |   | All OtherCompensation($) |    | Total  |   |
|------------------------------|--------|--------|--------|-----------|---------|--------|----------|--------|--------|----------------|--------|--------|-----------------|--------|--------|--------------------------|---------|--------|--------|
| (a)                          |   | (b)    |   | (c)       |    |   | (d)      |   |   | (e)            |   |   | (f)             |   |   | (i)                      |    |   | (j)    |   |
| Stephen W. Everett,          |   | 2009   |   | $         | 325,000 |   |     | $      | 25,000 | (1)            |   | $      | ---             |   |   | $                        | ---     |   |   | $ | 28,506 | (4) |   | $ | 378,506 |   |
| President and CEO            |   | 2008   |   | $         | 294,500 |   |     | $      | 50,000 | (2)            |   | $      | ---             |   |   | $                        | ---     |   |   | $ | 29,689 | (5) |   | $ | 374,189 |   |
|                         |   | 2007   |   | $         | 286,565 |   |     | $      | ---    |           |   | $      | ---             |   |   | $                        | ---     |   |   | $ | 23,999 | (6) |   | $ | 310,564 |   |
|                         |   |   |   |      |    |   |     |   |   |           |   |   |            |   |   |                     |    |   |   |   |   |   |   |   |   |   |
| Thomas K. Langbein           |   | 2009   |   | $         | 56,000  |   |     | $      | 15,000 | (1)            |   | $      | 31,320          | (7)    |   | $                        | ---     |   |   | $ | 166,489 | (8) |   | $ | 268,809 |   |
| Chairman of the Board and    |   | 2008   |   | $         | ---     |   |     | $      | ---    |           |   | $      | ---             |   |   | $                        | ---     |   |   | $ | --- |   |   | $ | --- |   |
| Chief of Strategic Alliances |   | 2007   |   | $         | ---     |   |     | $      | ---    |           |   | $      | ---             |   |   | $                        | ---     |   |   | $ | --- |   |   | $ | --- |   |
| and Investor Relations(3)    |   |   |   |      |    |   |     |   |   |           |   |   |            |   |   |                     |    |   |   |   |   |   |   |   |   |   |
|                         |   |   |   |      |    |   |     |   |   |           |   |   |            |   |   |                     |    |   |   |   |   |   |   |   |   |   |
| Andrew J. Jeanneret,         |   | 2009   |   | $         | 220,000 |   |     | $      | 15,000 | (1)            |   | $      | ---             |   |   | $                        | ---     |   |   | $ | 18,130 | (9) |   | $ | 253,130 |   |
| Vice President, Finance      |   | 2008   |   | $         | 202,955 |   |     | $      | 15,000 | (2)            |   | $      | ---             |   |   | $                        | 166,000 | (10)   |   | $ | 22,167 | (11) |   | $ | 406,122 |   |
| and Chief Financial          |   | 2007   |   | $         | 76,285  |   |     | $      | ---    |           |   | $      | ---             |   |   | $                        | ---     |   |   | $ | 3,887 | (12) |   | $ | 80,172 |   |
| Officer                      |   |   |   |      |    |   |     |   |   |           |   |   |            |   |   |                     |    |   |   |   |   |   |   |   |   |   |
|                         |   |   |   |      |    |   |     |   |   |           |   |   |            |   |   |                     |    |   |   |   |   |   |   |   |   |   |
| Thomas P. Carey,             |   | 2009   |   | $         | 183,000 |   |     | $      | 15,000 | (1)            |   | $      | ---             |   |   | $                        | ---     |   |   | $ | 10,537 | (13) |   | $ | 208,537 |   |
| Vice President,              |   | 2008   |   | $         | 159,577 |   |     | $      | 15,000 | (2)            |   | $      | ---             |   |   | $                        | ---     |   |   | $ | 11,647 | (14) |   | $ | 186,424 |   |
| Operations, COO              |   | 2007   |   | $         | 107,631 |   |     | $      | ---    |           |   | $      | ---             |   |   | $                        | 329,000 | (15)   |   | $ | 8,930 | (16) |   | $ | 445,561 |   |
|                         |   |   |   |      |    |   |     |   |   |           |   |   |            |   |   |                     |    |   |   |   |   |   |   |   |   |   |
| Daniel R. Ouzts,             |   | 2009   |   | $         | 170,000 |   |     | $      | 15,000 | (1)            |   | $      | ---             | (17)   |   | $                        | ---     |   |   | $ | 7,386 | (18) |   | $ | 192,386 |   |
| Vice President, Finance,     |   | 2008   |   | $         | 159,576 |   |     | $      | 10,000 | (2)            |   | $      | ---             | (17)   |   | $                        | ---     |   |   | $ | 1,794 | (19) |   | $ | 171,370 |   |
| Treasurer, and Principal     |   | 2007   |   | $         | 148,461 |   |     | $      | 0      |           |   | $      | ---             | (17)   |   | $                        | ---     |   |   | $ | 1,794 | (19) |   | $ | 150,255 |   |
| Accounting Officer           |   |   |   |      |    |   |     |   |   |           |   |   |            |   |   |                     |    |   |   |   |   |   |   |   |   |   |
|                         |   |   |   |      |    |   |     |   |   |           |   |   |            |   |   |                     |    |   |   |   |   |   |   |   |   |   |
| Joanne Zimmerman,            |   | 2009   |   | $         | 180,000 |   |     | $      | 15,000 | (1)            |   | $      | ---             | (17)   |   | $                        | ---     |   |   | $ | 11,310 | (20) |   | $ | 206,310 |   |
| Vice President, Clinical     |   | 2008   |   | $         | 159,577 |   |     | $      | 15,000 | (2)            |   | $      | ---             | (17)   |   | $                        | ---     |   |   | $ | 20,491 | (21) |   | $ | 195,168 |   |
| Services and Compliance      |   | 2007   |   | $         | 150,035 |   |     | $      | ---    |           |   | $      | ---             | (17)   |   | $                        | ---     |   |   | $ | 17,257 | (22) |   | $ | 167,292 |   |
| Officer                      |   |   |   |      |    |   |     |   |   |           |   |   |            |   |   |                     |    |   |   |   |   |   |   |   |   |   |

| (1)  | Accrued in 2009 and paid in 2010.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2)  | Accrued in 2008 and paid in 2009.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| (3)  | Became an executive employee in September, 2009.  Above represents total compensation during 2009 as Chairman of the Board ($191,388) (see Item 9, “Directors, Executive Officers and Corporate Governance – Compensation of Directors” above) and after becoming an employee.                                                                                                                                                                                                       |
| (4)  | Automobile expenses ($13,076) and medical, dental, life and long-term disability premiums ($15,430).                                                                                                                                                                                                                                                                                                                                                                                                             |
| (5)  | Automobile expenses ($11,442) and medical, dental, life and long-term disability premiums ($18,247).                                                                                                                                                                                                                                                                                                                                                                                                             |
| (6)  | Automobile expenses ($8,858) and medical, dental, life and long-term disability premiums ($15,141).                                                                                                                                                                                                                                                                                                                                                                                                              |
| (7)  | Includes (i) $11,080 grant date fair value of a February 27, 2009 stock award of 2,000 restricted shares that vested immediately, and (ii) $20,240 grant date fair value of a June 11, 2009 restricted stock unit award of 4,000 restricted shares that vest one year from the date of grant (see Item 9, “Directors, Executive Officers and Corporate Governance – Compensation of Directors” above).                                                                                         |
| (8)  | Includes medical and dental insurance premiums ($3,421) and an expense allowance ($3,000) after becoming an employee in September 2009, as well as $160,068 director compensation from January 1, 2009 until becoming an employee in September 2009.  Director compensation included (i) $147,000 reflecting the pro rated portion of the annual $200,000 stipend and $3,000 of non-employee director fees, (ii) $11,490 health and dental insurance premiums, and (iii) $1,578 auto-related expenses. |
| (9)  | Automobile expenses ($5,547) and medical, dental, life and long-term disability premiums ($12,673).                                                                                                                                                                                                                                                                                                                                                                                                              |
| (10) | Grant date fair value of a 50,000 share option granted February 29, 2008, exercisable at $12.18 per share and which vests in equal annual increments of 12,500 shares on February 27th of 2009 to 2012.                                                                                                                                                                                                                                                                                                          |
| (11) | Automobile expenses ($6,605) and medical, dental, life and long-term disability premiums ($15,562).                                                                                                                                                                                                                                                                                                                                                                                                              |

----

| (12) | Automobile expenses ($1,776) and medical, dental, and life insurance premiums ($2,111).                                                                                                                                                                                   |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (13) | Automobile expenses ($5,644) and medical and dental insurance premiums ($4,893).                                                                                                                                                                                          |
| (14) | Automobile expenses ($5,969) and medical and dental insurance premiums ($5,678).                                                                                                                                                                                          |
| (15) | Grant date fair value of a 50,000 share option granted April 16, 2007, exercisable at $12.18 per share and which vests in equal annual increments of 12,500 shares on April 15th of 2008 to 2011.                                                                         |
| (16) | Automobile expenses ($3,654), moving expenses ($2,761) and medical and dental insurance premiums ($2,515).                                                                                                                                                                |
| (17) | No amounts are reflected for stock awards granted June 27, 2006 that vested in equal annual increments on December 31st of 2006 to 2009, and for which 8,000 restricted share awards for each of Mr. Ouzts and Ms. Zimmerman each had a grant date fair value of $88,640. |
| (18) | Medical, dental and life insurance premiums.                                                                                                                                                                                                                              |
| (19) | Life insurance premiums.                                                                                                                                                                                                                                                  |
| (20) | Automobile expenses ($6,418) and medical and dental insurance premiums ($4,892).                                                                                                                                                                                          |
| (21) | Automobile expenses ($6,001) and medical and dental insurance premiums ($14,490).                                                                                                                                                                                         |
| (22) | Automobile expenses ($5,355) and medical and dental insurance premiums ($11,902).                                                                                                                                                                                         |

----

|                         |   |   |      |   |   | Estimated Future Payouts UnderEquity Incentive Plan Awards |   |   | All OtherStockAwards:Numberof Sharesof Stock |   |   | Grant DateFair Valueof Stockand |   |
|------------------------------|--------|--------|-----------|--------|--------|------------------------------------------------------------|--------|--------|----------------------------------------------|--------|--------|---------------------------------|--------|
|  Name                   |   |   | GrantDate |   |   | Threshold(#)                                               |   |   | Target(#)                                    |   |   | Maximum(#)                      |   |   | or Units(#) |   |   | OptionAwards |   |
| (a)                          |   |   | (b)       |   |   | (f)                                                        |   |   | (g)                                          |   |   | (h)                             |   |   | (i) |   |   | (l) |   |
| Thomas K. Langbein           |   |   | 2/27/2009 |   |   | ---                                                        |   |   |                                         | ---    |   |                            |   | --- |   |   |   | 2,000 | (3) |   | $ | 11,080 |   |
| Chairman of the Board and    |   |   | 6/11/2009 |   |   | ---                                                        |   |   |                                         | 4,000  | (2)    |                            |   | 4,000 | (2) |   |   | --- |   |   | $ | 20,240 |   |
| Chief of Strategic Alliances |   |   |      |   |   |                                                       |   |   |                                         |   |   |                            |   |   |   |   |   |   |   |   |   |   |   |
| and Investor Relations(1)    |   |   |      |   |   |                                                       |   |   |                                         |   |   |                            |   |   |   |   |   |   |   |   |   |   |   |

| (1) | Assumed position of Chief of Strategic Alliances and Investor Relations in September, 2009 in addition to continuing as Chairman of the Board. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Restricted stock units vesting June 10, 2010, one year from date of grant (has acceleration rights on change in control).                      |
| (3) | Share grants vested immediately.                                                                                                               |

----

|                                  |   | Option Awards                                  |   |   | Stock Awards                                |   |
|---------------------------------------|--------|------------------------------------------------|--------|--------|---------------------------------------------|--------|
|     Name (a) |   | Number ofSharesAcquired onExercise(#) (b) |   |   |  Value realizedon Exercise($) (c) |   |   | Number ofSharesAcquired onVesting(#) (d) |   |   |  Value Realizedon Vesting($) (e) |   |
|                                  |   |                                           |   |   |                                        |   |   |   |   |   |   |   |
| Thomas K. Langbein                    |   | ---                                            |   |   | $                                           | ---    |   |   |   | 2,000 | (1) |   | $ | 11,080 |   |
|                                  |   |                                           |   |   |                                        |   |   |   |   |   |   |   |   |   |   |
| Stephen W. Everett                    |   | ---                                            |   |   | $                                           | ---    |   |   |   | --- |   |   | $ | --- |   |
|                                  |   |                                           |   |   |                                        |   |   |   |   |   |   |   |   |   |   |
| Andrew J. Jeanneret                   |   | ---                                            |   |   | $                                           | ---    |   |   |   | --- |   |   | $ | --- |   |
|                                  |   |                                           |   |   |                                        |   |   |   |   |   |   |   |   |   |   |
| Thomas P. Carey                       |   | ---                                            |   |   | $                                           | ---    |   |   |   | --- |   |   | $ | --- |   |
|                                  |   |                                           |   |   |                                        |   |   |   |   |   |   |   |   |   |   |
| Daniel R. Ouzts                       |   | ---                                            |   |   | $                                           | ---    |   |   |   | 2,000 | (2) |   | $ | 14,360 |   |
|                                  |   |                                           |   |   |                                        |   |   |   |   |   |   |   |   |   |   |
| Joanne Zimmerman                      |   | ---                                            |   |   | $                                           | ---    |   |   |   | 2,000 | (2) |   | $ | 14,360 |   |

| (1) | February 27, 2009 director stock grants.  Shares vested immediately.                                                                                    |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | 8,000 shares of common stock granted on June 4, 2006 to each grantee, which vested in equal increments of 2,000 shares each December 31st from 2006 through 2009. |

----

|               |   | Option Awards                                                |   |   | Stock Awards                                                   |   |
|--------------------|--------|--------------------------------------------------------------|--------|--------|----------------------------------------------------------------|--------|
| Name               |   | NumberofSecuritiesUnderlyingUnexercisedOptions(#)Exercisable |   |   | NumberofSecuritiesUnderlyingUnexercisedOptions(#)Unexercisable |   |   | EquityIncentivePlanAwards:NumberofSecuritiesUnderlyingUnexercised UnearnedOptions(#) |   |   | OptionExercisePrice($) |   |   | OptionExpirationDate |   |   | Numberof Sharesor Unitsof StockThat HaveNotVested(#) |   |   | MarketValue ofShares orUnits ofStockThat HaveNotVested($) |   |
| (a)                |   | (b)                                                          |   |   | (c)                                                            |   |   | (d) |   |   | (e) |   |   | (f) |   |   | (g) |   |   | (h) |   |
|               |   |                                                         |   |   |                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Thomas K. Langbein |   |                                                         | ---    |   |                                                           |   | --- |   |   |   | --- |   |   | $ | --- |   |   |   | --- |   |   |   | 4,000 | (1) |   | $ | 28,720 |   |
|               |   |                                                         |   |   |                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stephen W. Everett |   |                                                         | ---    |   |                                                           |   | --- |   |   |   | --- |   |   | $ | --- |   |   |   | --- |   |   |   | --- |   |   |   | --- |   |
|               |   |                                                         |   |   |                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Daniel R. Ouzts    |   |                                                         | ---    |   |                                                           |   | --- |   |   |   | --- |   |   | $ | --- |   |   |   | --- |   |   |   | --- |   |   |   | --- |   |
|               |   |                                                         |   |   |                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Andrew J Jeanneret |   |                                                         | 25,000 | (2)    |                                                           |   | 25,000 | (2) |   |   | --- |   |   | $ | 12.18 |   |   | 2/29/13 |   |   |   | --- |   |   |   | --- |   |
|               |   |                                                         |   |   |                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Thomas P. Carey    |   |                                                         | 37,500 | (3)    |                                                           |   | 12,500 | (3) |   |   | --- |   |   | $ | 12.18 |   |   | 4/15/12 |   |   |   | --- |   |   |   | --- |   |
|               |   |                                                         |   |   |                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Joanne Zimmerman   |   |                                                         | ---    |   |                                                           |   | --- |   |   |   | --- |   |   | $ | --- |   |   |   | --- |   |   |   | --- |   |   |   | --- |   |

| (1) | Restricted stock units that vest one year from June 11, 2009 date of issuance.                                                                                                                                                                                               |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | An option exercisable at $12.18 per share to acquire an aggregate of 50,000 shares of company common stock which vests in equal increments of 12,500 shares on each February 28th 2009 through 2012.  The Offer under the Merger Agreement is at $11.25 per share. |
| (3) | An option exercisable at $12.18 per share to acquire an aggregate of 50,000 shares of company common stock which vests in equal increments of 12,500 shares on each April 15th 2008 through 2011.  The Offer under the Merger Agreement is at $11.25 per share.    |

----

|                                                       |   | Amount and Nature of Beneficial Ownership    |      |
|------------------------------------------------------------|--------|----------------------------------------------|-----------|
|  Name                                                 |   | Shares of Common StockBeneficially Owned (1) |      |   | Percentage of OutstandingShares Owned (%) (2) |   |
|                                                       |   |                                         |      |   |   |   |
| Thomas K. Langbein (3)                                     |   |                                         | 1,449,211 | (4) |   |   | 15.1 |   |
| Stephen W. Everett (5)                                     |   |                                         | 366,229   | (6) |   |   | 3.8 |   |
| Andrew J. Jeanneret (5)                                    |   |                                         | 26,500    | (7) |   |   | ** |   |
| Thomas P. Carey (5)                                        |   |                                         | 42,500    | (8) |   |   | ** |   |
| Daniel R. Ouzts (9)                                        |   |                                         | 143,913   | (10) |   |   | 1.5 |   |
| Joanne Zimmerman (11)                                      |   |                                         | 14,700    | (12) |   |   | ** |   |
| Peter D. Fischbein (3)*                                    |   |                                         | 163,871   | (13) |   |   | 1.7 |   |
| Robert W. Trause (3)*                                      |   |                                         | 27,917    | (14) |   |   | ** |   |
| Kenneth J. Bock(3)*                                        |   |                                         | 2,000     | (15) |   |   | ** |   |
| All directors and executiveofficers as a group (9 persons) |   |                                         | 2,236,841 | (16) |   |   | 23.1 |   |

| *   | Member of the Audit, Nominating and Compensation Committees                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **  | Less than 1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| (1) | A person is deemed to be the beneficial owner of securities that can be acquired by that person within 60 days from the above date that information concerning common stock ownership is provided, including, but not limited to, the exercise of options.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| (2) | Based on 9,610,373 shares of common stock outstanding at April 13, 2010.  Does not include 173,700 shares of non-vested restricted common stock to be but not yet issued under stock awards to 19 individuals, including officers and directors of the company, which stock vests in equal quarterly amounts on each August 12th from 2011 to 2014, with vesting accelerating upon a change in control of the company, including the Offer as discussed above in the Explanatory Note at the beginning of this Amendment No. 1 (“Restricted Stock Award”).  The awardee must be affiliated with the company at the time of vesting.  Each beneficial owner’s percentage ownership is determined by assuming any options held by such person (but not options held by any other person) and which are exercisable within 60 days of April 13, 2010, have been exercised and are outstanding only as to that person.  See note (1) above. |
| (3) | The address of such person is c/o Dialysis Corporation of America, 777 Terrace Avenue, Hasbrouck Heights, NJ 07604.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| (4) | Includes 4,000 restricted stock units vesting on June 10, 2010; vesting accelerates upon change in control of the company, which includes the Offer as described above in the Explanatory Note at the beginning of this Amendment No. 1.  Mr. Langbein must be affiliated with the company at the time of vesting.  All of Mr. Langbein’s shares are subject to a Tender and Voting Agreement under which Mr. Langbein has agreed to tender all his shares in accordance with the terms of the Offer and provide USRC and Merger Sub a proxy to vote his shares, primarily for the transactions contemplated in the Merger Agreement and against the approval or adoption of any Alternative Transaction.                                                                                                                                                                                                                                                               |
| (5) | The address of such person is c/o Dialysis Corporation of America, 1302 Concourse Drive, Suite 204, Linthicum, MD 21090.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| (6) | Includes 136,116 shares of common stock held by his wife.  Does not include 30,000 shares of non-vested common stock to be issued pursuant to a Restricted Stock Award.  See note (2) above.  Mr. Everett must be affiliated with the company at the time of vesting.  All of Mr. Everett’s shares are subject to a Tender and Voting Agreement.  See note (4) above.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

----

| (7)  | Includes: (i) 1,500 shares of common stock of the company held in his IRA account; and (ii) 25,000 shares of common stock of the company obtainable upon exercise of an option for an aggregate of 50,000 shares of common stock, at $12.18 per share through February 28, 2013.  Does not include: (i) the balance of the option for 25,000 shares of common stock, which option vests in equal increments of 12,500 shares on February 28, 2011 and 2012; Mr. Jeanneret must be affiliated with the company at the time of vesting; and (ii) 15,000 shares of non-vested common stock to be issued pursuant to a Restricted Stock Award.  See note (2) above.  All of Mr. Jeanneret’s shares are subject to a Tender and Voting Agreement.  See note (4) above.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (8)  | Includes 37,500 shares of common stock of the company obtainable upon exercise of an option for an aggregate of 50,000 shares of common stock, at $12.18 per share through April 15, 2012.  Does not include: (i) the balance of the option for 12,500 shares of common stock which vests on April 15, 2011; Mr. Carey must be affiliated with the company at the time of vesting; and (ii) 22,000 shares of non-vested common stock to be issued pursuant to a Restricted Stock Award.  See note (2) above.  All of Mr. Carey’s shares are subject to a Tender and Voting Agreement.  See note (4) above.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| (9)  | The address of such person is c/o Dialysis Corporation of America, 2337 West 76th Street, Hialeah, FL 33016.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| (10) | Does not include 15,000 shares of non-vested common stock to be issued pursuant to a Restricted Stock Award.  See note (2) above.  Mr. Ouzts must be affiliated with the Company at the time of vesting.  All of Mr. Ouzts’ shares are subject to a Tender and Voting Agreement.  See note (4) above.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| (11) | The address of such person is c/o Dialysis Corporation of America, 214 Senate Avenue, Suite 300, Camp Hill, PA 17011.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| (12) | Does not include 15,000 shares of non-vested common stock to be issued pursuant to a Restricted Stock Award.  See note (2) above.  All of Ms. Zimmerman’ shares are subject to a Tender and Voting Agreement.  See note (4) above.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| (13) | Includes: (i) 93,565 shares held by Mr. Fischbein individually; (ii) 63,308 shares held jointly with his wife; (iii) 4,998 shares held in trust for the benefit of his majority-age daughter for which Mr. Fischbein serves as sole trustee; and (iv) 2,000 restricted stock units vesting on June 10, 2010; vesting accelerates upon a change in control of the company including the Offer as discussed above in the Explanatory Note at the beginning of this Amendment No. 1.  Mr. Fischbein must be affiliated with the company at the time of vesting.  Does not include: (a) 112,586 (1.2%) shares of common stock held by his wife, who is economically independent and maintains a separate brokerage account with respect to these shares; (b) 68,000 shares held in trust for the benefit of Mr. & Mrs. Fischbein’s minority age son, with Mr. Fischbein’s wife serving as the sole trustee (Mr. Fischbein has no voting or dispositive power with respect to the common stock referred to in parts (a) and (b) above, and, accordingly, Mr. Fischbein disclaims beneficial interest in those shares of common stock); and (c) 12,000 shares of non-vested common stock to be issued pursuant to a Restricted Stock Award.  See note (2) above.  All of Mr. Fischbein’s shares are subject to a Tender and Voting Agreement.  See note (4) above. |
| (14) | Includes 2,000 restricted stock units vesting on June 10, 2010; vesting accelerates upon a change in control of the company including this Offer as discussed above in the Explanatory Note at the beginning of this Amendment No. 1.  Mr. Trause must be affiliated with the Company at the time of vesting.  Does not include 12,000 shares of non-vested common stock to be issued pursuant to a Restricted Stock Award.  See note (2) above.  All of Mr. Trause’s shares are subject to a Tender and Voting Agreement.  See note (4) above.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| (15) | Represents 2,000 restricted stock units vesting on June 10, 2010; vesting accelerates upon a change in control of the company including this Offer as discussed above in the Explanatory Note at the beginning of this Amendment No. 1.  Mr. Bock must be affiliated with the company at the time of vesting.  Does not include 4,000 shares of non-vested common stock to be issued pursuant to a Restricted Stock Award.  See note (2) above.  All of Mr. Bock’s shares are subject to a Tender and Voting Agreement.  See note (4) above.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| (16) | Includes: (i) two incentive options, each for 50,000 shares of common stock, one of which is vested and exercisable for 37,500 shares of common stock through April 15, 2012, and the other is vested and exercisable for 25,000 shares of common stock through February 28, 2013, each exercisable at $12.18 per share, see notes (7) and (8) above; and (ii) 10,000 restricted stock units vesting on June 10, 2010.  See notes (4) and (13) through (15) above.  Does not include (i) the non-vested portion of the two incentive options for an aggregate of 37,500 shares of common stock (see notes (7) and (8) above), and (ii) an aggregate of 125,000 shares of non-vested common stock to be issued pursuant to Restricted Stock Awards (see notes (4), (6) through (8), (10), (12) and (13) through (15) above).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

----

| Plan Category                                                 | Number of securities to beissued upon exercise ofoutstanding options, warrantsand rights | Weighted-averageexercise price ofoutstanding options,warrants and rights | Number of securitiesremaining available forfuture issuance under equitycompensation plans(excluding securities reflectedin column (a)) |
|---------------------------------------------------------------|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| (a)                                                           | (b)                                                                                      | (c)                                                                      |
|                                                          |                                                                                     |                                                                     |                                                                                                                                   |
| Equity compensation plansapproved by security holders:   | 40,000(1)                                                                                | $12.18                                                                   | 2,601,508(2)                                                                                                                           |
| Equity compensation plans notapproved by security holders:(3) | N/A                                                                                      | N/A                                                                      |                                                                                                                                   |

| (1) | Includes only vested portion of outstanding options at December 31, 2009 as follows: (i) 25,000 option shares under a five year option for a total of  50,000 shares exercisable through April 15, 2012 at $12.18 per share, vesting in equal increments of 12,500 shares each April 15, 2008 through 2011 (an additional 12,500 option shares subsequently vested on April 15, 2010); and (ii) an aggregate of 15,000 option shares under two separate five year options for an aggregate of 60,000 shares, exercisable through February 28, 2013 at $12.18 per share, vesting in the aggregate in equal increments of 15,000 shares each February 28, 2009 through February 28, 2012 (as of April 15, 2010, an additional 25,000 option shares subsequently vested and 2,500 option shares of the 15,000 option shares that had vested as of December 31, 2009 expired); does not include (a) an aggregate of 62,500 non-vested option shares as of December 31, 2009 (as of April 15, 2010, an aggregate of 25,000 option shares of those non-vested option shares at December 31, 2009 subsequently vested); and (b) 7,500 non-vested option shares cancelled in January, 2010, based upon the resignation of a key employee.  The options provide for adjustments under limited circumstances, and have termination and acceleration provisions. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (2)    | Reflects: (i) 2,000,000 shares reserved under the 2009 Incentive Plan; and (ii) 746,279 shares carried forward into the 2009 Incentive Plan from the 1999 Incentive Plan which expired in April, 2009, less (a) 110,000 shares for three outstanding options (40,000 shares vested (as of April 15, 2010, 62,000 option shares vested), 70,000 shares non-vested (as of April 15, 2010, 37,500 shares non-vested), of which 7,500 non-vested option shares were cancelled in January, 2010 and 2,500 option shares expired due to the resignation of the option holder); (b) 18,750 options exercised in June, 2009 (of which 9,854 shares used to exercise the options were reinstated to the 2009 Incentive Plan); (c) 19,375 non-vested stock awards; and (d) 6,500 vested stock awards. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| (3)    | There are employment agreements with six members of executive management, none of which specifically provides for the issuance of equity securities of the company.  Stephen W. Everett, President and CEO of the company, has an employment agreement which provided for the issuance of securities, which equity issuance portions of the agreement have expired.  Executive officers may be entitled to cash and equity bonuses from time to time within the guidelines of the company’s compensation policies, and as may be recommended by the Compensation Committee for approval by the board of directors.                                                                                                                                                |

| Name               | Date ofTransaction | Nature ofTransaction | Numberof Shares | Price/Share |
|--------------------|--------------------|----------------------|-----------------|-------------|
|               |               |                 |            |        |   |
| Stephen W. Everett | 4/13/2010          | *                    | 30,000          |        | $0.00 |
| Thomas Carey       | 4/13/2010          | *                    | 22,000          |        | $0.00 |
| Andrew Jeanneret   | 4/13/2010          | *                    | 15,000          |        | $0.00 |
| Daniel R. Ouzts    | 4/13/2010          | *                    | 15,000          |        | $0.00 |
| Joanne Zimmerman   | 4/13/2010          | *                    | 15,000          |        | $0.00 |
| Peter D. Fischbein | 4/13/2010          | *                    | 12,000          |        | $0.00 |
| Robert Trause      | 4/13/2010          | *                    | 12,000          |        | $0.00 |
| Kenneth Bock       | 4/13/2010          | *                    | 4,000           |        | $0.00 |

----

|   | ● | the basis and rationale for considering and entering into the transaction;                                                                                                                                                        |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | ● | alternatives to the related party transaction;                                                                                                                                                                                    |
|   | ● | whether the transaction is on terms at least as favorable as would be obtained from unaffiliated third parties; if an employment relationship is involved, then whether any such arrangement is available to employees generally; |
|   | ● | the potential for the transaction to lead to an actual or apparent conflict of interest, and whether there are any safeguards that could be imposed to prevent any conflict of interest;                                          |
|   | ● | the overall fairness of the transaction to all parties concerned, including our shareholders; and                                                                                                                                 |
|   | ● | related party transactions are strictly construed and would have to significantly further the interest of and be a benefit to the company and its shareholders.                                                                   |

|   | ● | disclosure of any potential related party transaction to the Audit Committee (the source could be the related party, any member of the Board, or any executive officer);                                        |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | ● | if any member of the Audit Committee appears to have a conflict or is otherwise involved in the transaction, such member would be recused from any deliberations and decisions relating to the transaction; and |
|   | ● | related party transactions should be approved in advance; but if not practicable, must be ratified as promptly as possible.                                                                                     |

----

|   | ● | amendment to the employment agreement of Thomas Carey, Vice President of Operations and Chief Operating Officer, to provide for increased noncompetition provisions and a $170,000 payment therefore at such time USRC purchases the common stock of the company and its designated directors are appointed to the board; see Item 9, “Directors, Executive Officers and Corporate Governance – Corporate Governance – Analysis of Executive Compensation” above; and |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | ● | termination payments to officers and directors upon a change in control as defined in their employment agreements; see Item 10, “Executive Compensation” subtitles “Termination Payments” and “Potential Payments upon Termination In Compensation with a Change in Control and Pursuant to the Merger Agreement” above.                                                                                                                                  |

----

| Year Ended December 31 |   | 2009   |    |   | 2008   |   |
|------------------------|--------|--------|---------|--------|--------|--------|
|                   |   | Fees   |    |   | %      |   |   | Fees |   |   | % |   |
| Audit fees (1)         |   | $      | 130,500 |   |   |   | 70.7 |   |   | $ | 121,000 |   |   |   | 48.6 |   |
| Audit-Related fees (2) |   |   | 9,000   |   |   |   | 4.9 |   |   |   | 74,500 |   |   |   | 29.9 |   |
| Tax fees (3)           |   |   | 45,000  |   |   |   | 24.4 |   |   |   | 51,025 |   |   |   | 20.5 |   |
| All other fees         |   |   | 0       |   |   |   | --- |   |   |   | 2,250 |   |   |   | 1.0 |   |
| Total                  |   | $      | 184,500 |   |   |   | 100.0 |   |   | $ | 248,775 |   |   |   | 100.0 |   |

| (1)    | For professional services in connection with the review and audit of the company’s annual financial statements for the years ended December 31, 2009 and 2008; and the review of the company’s interim financial statements included in the quarterly reports on Form 10-Q during the years ended December 31, 2009 and 2008.                                                                                                                          |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| (2)    | Audit-related fees were for professional services rendered in connection with employee benefit plan audits for 2009 ($9,000) and 2008 ($7,500), and due diligence services related to accounting and tax matters in connection with potential business combinations, including, among others, review of financial statements, financial data and records and discussions with other auditors and accounting personnel, which was $0 for 2009 and $67,000 for 2008. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| (3)    | For tax related services, none of which impaired the auditors’ independence.                                                                                                                                                                                                                                                                                                                                                                                 |

----

| (b)    | Exhibits +                |
|--------|---------------------------|
|   |                      |   |
|   | 10                        | Material Contracts |
|   |                      |   |
|   | 10.33                     | Agreement and Plan of Merger By and Among U.S. Renal Care, Inc., Urchin Merger Sub, Inc., and the Company dated April 13, 2010 (incorporated by reference to the Company’s Current Report on Form 8-K dated April 19, 2010 (“April 2010 Form 8-K”), Item 9.01(2)A)). |
|   |                      |   |
|   | 10.34                     | Form of Tender Offer and Voting Agreement By and Among U.S. Renal Care, Inc., Urchin Merger Sub, Inc., the Company and certain shareholders of the Company dated April 13, 2010 (incorporated by reference to the Company’s April 2010 Form 8-K, Item 9.01(2)(B)). |
|   |                      |   |
|   | 10.35                     | First Amendment to the Employment Agreement between the Company and Stephen W. Everett dated April 13, 2010 (incorporated by reference to the Company’s April 2010 Form 8-K, Item 9.01(10)(K)).* |
|   |                      |   |
|   | 10.36                     | First Amendment to the Employment Agreement between the Company and Thomas K. Langbein dated April 13, 2010 (incorporated by reference to the Company’s April 2010 Form 8-K, Item 9.01(10)(L)).* |
|   |                      |   |
|   | 10.37                     | First Amendment to the Employment Agreement between the Company and Thomas P. Carey dated April 13, 2010 (incorporated by reference to the Company’s April 2010 Form 8-K, Item 9.01(10)(J)).* |
|   |                      |   |
|   | 31                        | Rule 13a-14(a)/15d-14(a) Certifications. |
|   |                      |   |
|   | 31.1                      | Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934. |
|   |                      |   |
|   | 31.2                      | Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934. |
|   |                      |   |
|   | 32                        | Section 1350 Certifications |
|   |                      |   |
|   | 32.1                      | Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350(3). |
|   |                      |   |
|   | _________________________ |
|   |                      |   |
|   |                      |   |
|   | +                         | Documents incorporated by reference not included in Exhibit Volume. |
|   |                      |   |
|   | *                         | Management contract or compensatory plan or arrangement. |

----

|   | DIALYSIS CORPORATION OF AMERICA |
|--------|---------------------------------|
|   |                            |   |   |
|   |                            |   |   |
|   | By:                             | /s/ STEPHEN W. EVERETT |   |
|   |                            | Stephen W. Everett |   |
|   |                            | President and Chief Executive Officer |

----

| 31.1   | Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934                                                        |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                              |
| 31.2   | Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934                                                        |
|   |                                                                                                                                                              |
| 32.1   | Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 |